Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.75 |
| ▸ | MAOA | P21397 | 1/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9417738 | 1.00 | TAAR1 (0.75) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL17413364 | 1.00 | TAAR1 (0.75) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Hydrochloric Acid SCHEMBL1191450 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Hydrochloric Acid SCHEMBL27621318 | 0.98 | TAAR1 (0.72) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL27560699 | 0.91 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL27852110 | 0.91 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL4624045 | 0.91 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL27637944 | 0.91 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL13747797 | 0.86 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL2636 | 0.86 | SLC6A2 (1.00) | TAAR1SLC6A2SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528749-A | Synthesis method of (r) -tert-butyl (1- ([ 1,1' -biphenyl ] -4-yl) -3-hydroxy propane-2-yl) carbamate | 河北八亿时空药业有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119528749-A | Synthesis method of (r) -tert-butyl (1- ([ 1,1' -biphenyl ] -4-yl) -3-hydroxy propane-2-yl) carbamate | 河北八亿时空药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-110114368-B | Targeted mutant interferon-gamma and uses thereof | 奥睿尼斯生物科学私人有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1135106-B1 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS | PENWEST PHARMACEUTICALS CO (US) | 2008-04-09 | — | — | EP | disclosed |
| CN-1886164-A | Package for pharmaceutical preparations | ALZA CORP (US) | 2006-12-27 | — | — | CN | disclosed |
| CN-1886100-A | Surfactant-based gels as injectable sustained drug delivery vehicles | ALZA CORP (US) | 2006-12-27 | — | — | CN | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| EP-1135106-A4 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS | PENWEST PHARMACEUTICALS CO (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1135106-A1 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS | Edward Mendell Co., Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001022940-A1 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS | EDWARD MENDELL CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | TAAR1 74/4885SLC6A2 1374/4885SLC6A4 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.